Tradestie Institutional Equity Comparison Engine

COCP vs ENTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ENTX Overall Edge

ENTX Captures Institutional Edge (3โ€“0 Pillars ยท 6โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus ENTX at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
COCP N/M vs ENTX N/M Fwd P/E
Growth & Margin Winner ENTX
Op Margin -3063.6% vs 0.0% ยท YoY +26.9% vs -100.0%
Momentum & Technical Winner ENTX
1Y -1.5% vs +11.1% ยท 52W Pos 20% vs 64%
Options & Structure Winner ENTX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (32nd %ile IV)
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.82% 1D
Market Cap $18.9M
1M Return +7.23%
1Y Return -1.46%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 54.0
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap $541.6M
1M Return +2.38%
1Y Return +11.07%
Forward P/E N/M
Unified AI Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: COCP -1.46% ENTX +11.07% Spread: +12.53 pp (ENTX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period COCP Revenue ENTX Revenue COCP Op. Margin ENTX Op. Margin Margin Edge
FY2011 $10M N/A -30.6% N/A COCP
FY2019 $10M N/A -737.4% N/A COCP
FY2020 $0M $0M -476.0% -3059.7% COCP
FY2021 N/A $0M N/A -2139.6% ENTX
FY2022 N/A $0M N/A -9714.2% ENTX
FY2024 N/A $0M N/A -5295.6% ENTX
FY2025 N/A $0M N/A -27450.0% ENTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: COCP (1) vs ENTX (6)
Institutional Metric COCP ENTX Criterion Row Winner
Market Capitalization Scale $18.9M $541.6M Larger Scale ENTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +26.9% -100.0% Higher Growth COCP
Operating Margin (TTM) Profitability -3063.6% 0.0% Higher Margin ENTX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -311.7% -20.3% Higher ROE ENTX
52-Week Range Position Momentum 20% ($1โ€“$2) 64% ($1โ€“$4) Stronger Trend ENTX
Beta / 30D Volatility Risk Regime 0.97ฮฒ ยท 55% Vol 1.07ฮฒ ยท 45% Vol Lower Realized Risk ENTX
Unified Institutional Score Composite Signal 38.7 / 100 (SELL) 53.5 / 100 (HOLD) Higher Composite ENTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full COCP vs ENTX Buy Guide
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 32nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither COCP nor ENTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.